Deals Of The Week: Eisai Shares Full Compound Library In Screening Partnership With JHU
Academic drug-discovery collaborations with industry usually are limited by restraints companies place on how much of their compound libraries they’ll share in a collaboration. Plus the week’s top deals, including M&A transactions between Teva and NuPathe, and Par Pharmaceuticals and JHP.
You may also be interested in...
Sanofi links with researchers at Germany’s Fraunhofer Gesellschaft in the search for new antibiotics while a European joint venture called Hit Discovery Constance GmbH is set up to conduct high-throughput screening for biotech and academic partners. Also, Moderna Therapeutics bags another major partner, GSK exits its DMD deal with Prosensa, and more.
As academic labs fill gaps in discovery work once performed by biopharma companies, Roche is confident that a U.S. consortium of academic drug-discovery units will lead to broader partnerships between industry and academia and within the academy itself. Plus, MedImmune acquires ADC specialist Spirogen and other deals from the past week.
Allergan/MAP Planned Merger, Approval Of NuPathe’s Triptan Patch Change U.S. Landscape For Migraine Therapy
While Allergan plans to diversify its portfolio in migraine by acquiring partner MAP and its candidate for acute migraine, NuPathe seeks a partner for a triptan patch product expected to avoid the nausea suffered by many migraine patients.